Skip to content
Back to meeting Original
CancerTherapyAdvisor· @CancerTherAdvsr · X·· 5 days agoScore70
Body

At #ESMO26, results from the Phase 2 DOVACC trial showed adding the UV1 cancer vaccine to olaparib +/- durvalumab did not significantly improve PFS in BRCA wild-type recurrent ovarian cancer🧬

@myESMO #ESMO2026

Full article: https://bit.ly/3UaDJVt

84 views · 0 likes · 0 reposts · 0 replies

Source: CancerTherapyAdvisor · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.